"Scientific evaluation of Basti therapy in the treatment of Prostate"

"Scientific evaluation of Basti therapy in the treatment of Benign Prostatic Hyperplasia"

Status

Active, not recruiting

Phases

Phase 2Phase 3

Study type

Interventional

Source

CTRI

Registry ID

CTRI/2020/10/028309

Enrollment

Registered

2020-10-09

Start date

Unknown

Completion date

Unknown

Last updated

2021-11-24

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: N401- Benign prostatic hyperplasia withlower urinary tract symptoms

Interventions

Intervention1: Group A 10 patients will be treated with (Dutasteride 0.5 mg & Tamsulosin 0.4 mg) OD HS for 21 days : Group B 10 Patients will be treated with Oral Medicine. Gokshura Churna 3 gm

Eligibility

Inclusion criteria

Inclusion criteria: Diagnosed case of Benign Enlargement of prostate

Exclusion criteria

Exclusion criteria: Neurogenic bladder Uretheral Stricture Carcinoma Prostate Uncontrolled Diabetes Mellitus Subjects with ARF and CRF Subjects with Venereal Diseases HIV & HBsAg positive subjects

Design outcomes

Primary

Measure	Time frame
Decrease in Pain continuation in urine flowTimepoint: 1 month	—

Secondary

Measure	Time frame
incomplete emptying frequency intermittency urgency weak stream straining noctuiaTimepoint: 1 month	—

Countries

India

Contacts

Public ContactDr A K Dwivedi

IMS BHU

jalindrageeta@gmail.com8502827954

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026